Cytek Biosciences (CTKB) CTO Yan Ming reports bona fide gift of shares

Rhea-AI Filing Summary

Cytek Biosciences, Inc. director and Chief Technology Officer Yan Ming reported a bona fide gift of common stock. On the reported date, Ming transferred 135,892 shares of Cytek Biosciences common stock as a gift at a stated price of $0.00 per share. After this disposition, Ming continued to hold 4,796,688 shares of common stock directly, indicating that the gifted amount represents a relatively small portion of his overall reported holdings. As a gift transaction, this Form 4 reflects a non-market transfer rather than an open-market purchase or sale.

Insider Trade Summary

135,892 shares gifted

Mixed 1 txn

Insider Yan Ming

Role CHIEF TECHNOLOGY OFFICER

Type	Security	Shares	Price	Value
Gift	Common Stock	135,892	$0.00	--

Holdings After Transaction: Common Stock — 4,796,688 shares (Direct, null)

Footnotes (1)

Key Figures

Gifted shares: 135,892 shares Post-transaction holdings: 4,796,688 shares Gift price per share: $0.00 per share +2 more

5 metrics

Gifted shares 135,892 shares Common stock gifted on June 12, 2026

Post-transaction holdings 4,796,688 shares Common stock held directly after gift

Gift price per share $0.00 per share Stated transaction price for bona fide gift

Transaction code G Indicates bona fide gift of common stock

Transaction direction Dispose Form 4 classifies action as a gift transfer disposition

Key Terms

Form 4, bona fide gift, transaction code G, non-derivative common stock, +1 more

5 terms

Form 4 regulatory

"This Form 4 reflects a non-market transfer rather than an open-market purchase or sale."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

bona fide gift financial

"Ming reported a bona fide gift of common stock."

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

transaction code G regulatory

"The transaction code was “G,” indicating a bona fide gift."

non-derivative common stock financial

"The reported transaction involves only non-derivative common stock."

disposition financial

"The Form 4 classifies action as a gift transfer disposition."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yan Ming

(Last) (First) (Middle)

C/O CYTEK BIOSCIENCES, INC.

47215 LAKEVIEW BOULEVARD

(Street)

FREMONT CALIFORNIA 94538

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cytek Biosciences, Inc. [ CTKB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF TECHNOLOGY OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/12/2026		G		135,892	D	$0	4,796,688	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Valerie Barnett, Attorney-in-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Cytek Biosciences (CTKB) report for Yan Ming?

Cytek Biosciences reported that Chief Technology Officer and director Yan Ming made a bona fide gift of 135,892 shares of common stock. The Form 4 classifies this as a gift transfer, not an open-market purchase or sale.

How many Cytek Biosciences (CTKB) shares did Yan Ming gift in this Form 4?

Yan Ming gifted 135,892 shares of Cytek Biosciences common stock. The transaction code was “G,” indicating a bona fide gift, and the stated transaction price per share was $0.00, consistent with a non-cash transfer.

How many Cytek Biosciences (CTKB) shares does Yan Ming hold after the gift?

Following the reported gift, Yan Ming holds 4,796,688 shares of Cytek Biosciences common stock directly. This post-transaction holding figure comes from the Form 4’s “shares following transaction” disclosure for his direct ownership.

Was the Cytek Biosciences (CTKB) Yan Ming transaction a buy or sell?

The transaction was neither a buy nor a sell; it was a bona fide gift. The Form 4 uses transaction code “G” and describes the action as a gift transfer, so it does not represent an open-market trade.

Does the Yan Ming Form 4 for Cytek Biosciences (CTKB) involve derivative securities?

No, the reported transaction involves only non-derivative common stock. The Form 4 shows no derivative transactions for this event and lists an empty derivative position summary in the filing data provided.